M&A Deal Summary

Sanofi Acquires Merial

On July 30, 2009, Sanofi acquired medical products company Merial from Merck for 4.0B USD

Acquisition Highlights
  • This is Sanofi’s 2nd transaction in the Medical Products sector.
  • This is Sanofi’s 3rd largest (disclosed) transaction.
  • This is Sanofi’s 2nd transaction in the United States.
  • This is Sanofi’s 1st transaction in Georgia.

M&A Deal Summary

Date 2009-07-30
Target Merial
Sector Medical Products
Buyer(s) Sanofi
Sellers(s) Merck
Deal Type Divestiture
Deal Value 4.0B USD

Target

Merial

Duluth, Georgia, United States
website
Merial Ltd. is an animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals.

Search 194,004 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sanofi

Paris, France

website


Category Company
Founded 1994
Sector Life Science
Employees99,412
Revenue 45.4B EUR (2022)
DESCRIPTION

Sanofi is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi was founded in 1994 and is based in Paris, France.


DEAL STATS #
Overall 6 of 27
Sector (Medical Products) 2 of 4
Type (Divestiture) 2 of 3
State (Georgia) 1 of 1
Country (United States) 2 of 16
Year (2009) 5 of 8
Size (of disclosed) 3 of 13
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-07-28 Shantha Biotechnics

Hyderabad, India

Shantha Biotechnics Ltd. is a biotechnology company, that researches and develops vaccines.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-10-01 Fovea Pharmaceuticals SA

Paris, France

Fovea Pharmaceuticals was set up in 2005 to research and develop drugs for treating ophthalmologic disorders, such as age-related macular degeneration, retinitis pigmentosa and diabetic retinopathy. Fovea has developed a range of products in different stages of testing, from pre-clinical products to products about to undergo clinical testing. Over recent years Fovea has signed exclusive cooperation agreements with CombinatorRx Inc. and Novartis.

Buy €370M

Seller(S) 1

SELLER

Merck

Rahway, New Jersey, United States

website


Category Company
Founded 1891
Sector Life Science
Employees67,000
Revenue 59.3B USD (2022)
DESCRIPTION
Merck office in Palo Alto, California.
Merck office in Palo Alto, California.

Merck is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The Company’s operations are comprised of four operating segments. These include Pharmaceutical, Animal Health, Consumer Care and Alliances. Merck's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products. Merck was established in 1891 and is based in Rahway, New Jersey.


DEAL STATS #
Overall 1 of 7
Sector (Medical Products) 1 of 1
Type (Divestiture) 1 of 6
State (Georgia) 1 of 1
Country (United States) 1 of 7
Year (2009) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-09-11 NovaCardia

San Diego, California, United States

NovaCardia, Inc. is a pharmaceutical company focuses on the development and commercialization of small molecule drugs for the treatment of cardiovascular diseases.

Buy $366M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-11-03 Schering-Plough

Kenilworth, New Jersey, United States

Schering-Plough Corp. is a manufacturer and sells pharmaceuticals.

Buy $41.1B